MDR1 Cancer Research Results

MDR1, Multidrug Resistance 1: Click to Expand ⟱
Source:
Type: gene
MDR-1 (Multidrug Resistance 1) is a gene that plays a crucial role in the development of resistance to chemotherapy in cancer cells. The MDR-1 gene encodes for a protein called P-glycoprotein (P-gp), which is a transmembrane efflux pump that helps to remove toxic substances, including chemotherapy drugs, from cells.
MDR-1 is often overexpressed in various types of cancer, including: Leukemia, Lymphoma, Breast, Lung, Ovarian, CRC.
Scientific Papers found: Click to Expand⟱
5434- AG,    Recent Advances in the Mechanisms and Applications of Astragalus Polysaccharides in Liver Cancer Treatment: An Overview
- Review, Liver, NA
AntiCan↑, Apoptosis↑, TumCP↓, EMT↓, Imm↑, ChemoSen↑, BioAv↓, TumCG↓, IL2↑, IL12↑, TNF-α↑, P-gp/ABCB1↓, MDR1↓, QoL↑, Casp↑, DNAdam↑, Bcl-2↓, BAX↑, MMP↓, Cyt‑c↑, NOTCH1↓, GSK‐3β↓, TumCCA↑, GSH↓, ROS↑, lipid-P↑, c-Iron↑, GPx4↓, ACSL4↑, Ferroptosis↑, Wnt↓, β-catenin/ZEB1↓, cycD1/CCND1↓, Akt↓, PI3K↓, mTOR↓, CXCR4↓, Vim↓, PD-L1↓, eff↑, eff↑, ChemoSen↑, ChemoSen↑, chemoP↑,
5553- BBM,    A review on berbamine–a potential anticancer drug
- Review, Var, NA
P-gp/ABCB1↓, MDR1↓, survivin↓, NF-kB↓, TumCP↓, TumCCA↑, Apoptosis↑, SMAD3↑, P21↑, cycD1/CCND1↓, cMyc↑, Bcl-2↓, Bcl-xL↓, BAX↑, CaMKII ↓, ChemoSen↑, MMP2↓, MMP9↓, TIMP1↑, cl‑Casp3↑, cl‑Casp9↑, cl‑Casp8↑, cl‑PARP↑, IL6↓, ROS↑,
1397- BBR,  Chemo,    Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells
- in-vitro, Lung, A549
TumCG↓, ROS↑, MDR1↓,
5181- BBR,  Cisplatin,    Berberine Improves Chemo-Sensitivity to Cisplatin by Enhancing Cell Apoptosis and Repressing PI3K/AKT/mTOR Signaling Pathway in Gastric Cancer
- in-vitro, GC, SGC-7901 - in-vitro, GC, BGC-823
tumCV↓, MDR1↓, ChemoSen↑, PI3K↓, Akt↓, mTOR↓,
5659- BNL,    Borneol, a messenger agent, improves central nervous system drug delivery through enhancing blood–brain barrier permeability: a preclinical systematic review and meta-analysis
- Review, Var, NA
BBB↑, P-gp/ABCB1↓, MDR1↓, HIST1H3B?,
5660- BNL,    Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System
- Review, Var, NA
TumMeta↓, BBB↑, EPR↑, toxicity↓, BioAv↑, ChemoSen↑, eff↑, other↑, P-gp/ABCB1↓, MDR1↓, ROS↑, TumCCA↑, other↝, BioAv↓, DNAdam↑, BioEnh↑,
5764- CAPE,    Caffeic Acid Phenethyl Ester (CAPE), Derived from a Honeybee Product Propolis, Exhibits a Diversity of Anti-tumor Effects in Preclinical Models of Human Breast Cancer
- vitro+vivo, BC, MCF7 - NA, BC, MDA-MB-231
TumCG↓, TumCCA↑, Apoptosis↑, NF-kB↓, MDR1↓, VEGF↓, angioG↓,
5965- CEL,  Cisplatin,    Celecoxib enhances anticancer effect of cisplatin and induces anoikis in osteosarcoma via PI3K/Akt pathway
- in-vitro, OS, MG63
COX2/PTGS2↓, ChemoSen↑, MDR1↓, MRP1/ABCC1↓, E-cadherin↓, β-catenin/ZEB1↓, Apoptosis↑, TumCCA↑, TumCG↓, P-gp/ABCB1↓, PI3K↓, Akt↓,
2803- CHr,  5-FU,    Potentiating activities of chrysin in the therapeutic efficacy of 5-fluorouracil in gastric cancer cells
- in-vitro, GC, AGS
ChemoSen↑, TumCCA↑, Synergy↑, MDR1↓,
466- CUR,    Curcumin circumvent lactate-induced chemoresistance in hepatic cancer cells through modulation of hydroxycarboxylic acid receptor-1
- in-vitro, Liver, HepG2 - in-vitro, Liver, HuT78
GlucoseCon↓, lactateProd↓, pH↑, NO↑, LAR↓, Hif1a↓, LDHA↓, MCT1↓, MDR1↓, STAT3↓, HCAR1↓,
1057- EVO,    Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion
- in-vitro, Var, NA
NF-kB↓, TNF-α↓, COX2/PTGS2↓, cycD1/CCND1↓, cMyc↓, MMP9↓, ICAM-1↓, MDR1↓, XIAP↓, Bcl-2↓, Bcl-xL↓, IAP1↓, IAP2/BIRC3↓, cFLIP↓, Bfl-1↓,
7064- GamB,    Gambogic acid inhibits the catalytic activity of human topoisomerase IIα by binding to its ATPase domain
- in-vitro, GC, SGC-7901 - in-vitro, Liver, Bel-7402 - in-vitro, HCC, SMMC-7721 cell - in-vitro, Ovarian, HO-8910
TOP2↓, DNAdam↑, MDR1↓,
7102- GEN,    Genistein: An Integrative Overview of Its Mode of Action, Pharmacological Properties, and Health Benefits
- Review, Var, NA
*antiOx↑, *Inflam↓, *Bacteria↓, *AntiViral↑, *Dose↝, *AntiDiabetic↑, angioG↑, Apoptosis↑, tumCV↓, MyD88↑, Beclin-1/ATG6↑, LC3II↑, TLR4↑, TumAuto↑, mTOR↓, p62↓, TumCCA↑, TumCP↓, Akt↑, P53↑, DNMT3B↓, MEK↓, hTERT/TERT↓, VEGF↓, NF-kB↓, IAP1↓, MDR1↓, p‑Akt↓, Synergy↑, ChemoSen↑,
7679- iod,    Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin
- in-vivo, BC, MCF7
AntiTum↑, tumCV↓, Apoptosis↑, Bax:Bcl2↑, Bcl-2↓, MDR1↑, PPARγ↑, CD44↓,
9252- ISO, IH,    Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery
- Review, Var, NA
TumCP↓, Apoptosis↑, Casp↑, mtDam↑, MMPs↓, VEGF↓, EMT↓, *antiOx↓, *Inflam↓, *ROS↓, MDR1↓, PI3K↓, Akt↓, MAPK↓, NF-kB↓, Ingr↝, TumCCA↑, CycB/CCNB1↓, CDK1↓, P21↑, ROS↑, AMPK↑, *Ferroptosis↓, *NRF2↑, *HO-1↑, *IronCh↑, *lipid-P↓, *GSH↑, *ACSL4↓, *COX2/PTGS2↓, VEGF↓, angioG↓, E-cadherin↑, N-cadherin↓, uPA↓, *NK cell↑, radioP↑, Imm↑, Neut↑, Eos↑,
2180- itraC,    Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
- Review, Var, NA
Dose↝, toxicity↝, BioAv↑, Half-Life↝, BioAv↑, Dose↝, HH↓, TumAuto↑, Akt↓, mTOR↓, angioG↓, MDR1↓, TumCP↓, ChemoSen↑,
2179- itraC,    Repurposing itraconazole for the treatment of cancer
- Review, Var, NA
HH↓, angioG↓, TumCCA↑, MDR1↓, P-gp/ABCB1↓, mTOR↓, VEGF↓, Smo↓, Gli1↓, OS↑, PSA↓,
8047- IVM,    The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug
- Review, Var, NA
Half-Life↝, MDR1↓, P-gp/ABCB1↓, mtDam↑, ROS↑, OCR↓, compI↓, MMP↓, mt-SOD↑, ATP↓, p‑Akt↓, p‑mTOR↓, eff↓, ICD↑, TumAuto↑, PAK1↓, Wnt↓, TCF↓, Nanog↓, SOX2↓, CSCs↓, CD44↓, CD24↓, Dose↝,
8040- IVM,    Ivermectin, a potential anticancer drug derived from an antiparasitic drug
- Review, Var, NA
Akt↓, mTOR↓, TumAuto↑, TumCP↓, TumCCA↑, Wnt↓, YAP/TEAD↓, MMP↓, mitResp↓, ATP↓, eff↓, eff↑, ROS↑, ChemoSen↑, PAK1↓, MAPK↓, EMT↓, Beclin-1/ATG6↑, ATG5↑, CSCs↓, STAT3↝, P-gp/ABCB1↓, MDR1↓, HSP27↓, Chl↑, TFE3↑,
8055- KAE,    Molecular Mechanisms of the Anticancer Activity of the Flavonoid Kaempferol: A Comprehensive Review
- Review, Var, NA
antiNeop↑, *toxicity↓, TumCCA↑, ROS↑, ER Stress↑, TumAuto↑, Pyro↑, Ferroptosis↑, angioG↓, Imm↝, Synergy↑, ChemoSen↑, MPT↑, MMP↓, mtDam↑, Cyt‑c↑, Bax:Bcl2↑, Fas↑, DR4↑, DR5↑, JNK↑, ERK↑, CHOP/DDIT3↑, ER Stress↑, UPR↑, Ca+2↑, PI3K↓, Akt↓, mTOR↓, AMPK↑, *Ferroptosis↓, *antiOx↑, *NRF2↑, *GPx4↑, *ROS↓, *MDA↓, *i-Iron↓, *xCT/SLC7A11↑, VEGF↓, Wnt↓, β-catenin/ZEB1↓, EMT↓, STAT3↓, M2 MC↓, MCP1/CCL2↓, MMP9↓, MMP2↓, TIMP2↓, ChemoSen↑, PKM2↑, Glycolysis↓, CSCs↓, SOX4↓, OCT4↓, CD44↓, Nanog↓, MDR1↓, *GutMicro↑,
8190- LGE,  doxoR,    Cymbopogon citratus and Citral Overcome Doxorubicin Resistance in Cancer Cells via Modulating the Drug's Metabolism, Toxicity, and Multidrug Transporters
- in-vitro, BC, MCF7 - in-vitro, Liver, HepG2 - in-vitro, Ovarian, SKOV3
ChemoSen↑, CYP3A4↓, PXR, NR1I2↓, GSTA1↓, MDR1↓, MRP1/ABCC1↓, ABCG2↓,
2909- LT,    Revisiting luteolin: An updated review on its anticancer potential
- Review, Var, NA
Apoptosis↑, TumCCA↑, angioG↓, TumMeta↓, TumCP↓, chemoP↑, MDR1↓,
2914- LT,    Therapeutic Potential of Luteolin on Cancer
- Review, Var, NA
*antiOx↑, *IronCh↑, *toxicity↓, *BioAv↓, *BioAv↑, DNAdam↑, TumCP↓, DR5↑, P53↑, JNK↑, BAX↑, cl‑Casp3↑, cl‑Casp8↑, cl‑Casp9↑, cl‑PARP↑, survivin↓, cycD1/CCND1↓, CycB/CCNB1↓, CDC2↓, P21↑, angioG↓, MMP2↓, AEG1↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP9↓, CXCR4↓, PI3K↓, Akt↓, ERK↓, TumAuto↑, LC3B-II↑, EMT↓, E-cadherin↑, N-cadherin↓, Wnt↓, ROS↑, NICD↓, p‑GSK‐3β↓, iNOS↓, COX2/PTGS2↓, NRF2↑, Ca+2↑, ChemoSen↑, ChemoSen↓, IFN-γ↓, RadioS↑, MDM2↓, NOTCH1↓, AR↓, TIMP1↑, TIMP2↑, ER Stress↑, CDK2↓, Telomerase↓, p‑NF-kB↑, p‑cMyc↑, hTERT/TERT↓, RAS↓, YAP/TEAD↓, TAZ↓, NF-kB↓, NRF2↓, HO-1↓, MDR1↓,
8648- MBZ,    Mebendazole as a Candidate for Drug Repurposing in Oncology: An Extensive Review of Current Literature
- Review, Var, NA
angioG↓, MMPs↓, MDR1↓, TubPol↓, RadioS?, ChemoSen?, TumCG↓, TumMeta?, OS↑, BioAv↓, BioAv↑, BBB↑, mitA↑, HH↓, Shh↓, Synergy↑, Gli1↓, PTCH2↓, XIAP↓, cl‑PARP↑, Casp3↑, BRAF↓, MEK↓, SYN1↑, Cyt‑c↑, TumVol↓, VEGFR2/KDR/Flk1↓, VEGF↓, VCAM-1↓, DYRK1B↓, QoL↑, Dose↝,
8486- MF,    Silent forces, hidden currents: the influence of static magnetic field stimulation on tumor biophysics
- Review, Var, NA
Ca+2↑, TumCG↓, MMP↓, CellMemb↑, SOX2↓, Nanog↓, cMyc↓, CD44↓, CD133↓, P53↑, ROS↑, DNAdam↑, CDK1↓, CycB/CCNB1↓, TumCCA↑, TumCP↓, pH↓, TumCP↓, Telomerase↓, ChemoSen↑, TRPV1↝, Bax:Bcl2↑, Casp3↑, Akt↓, mTOR↓, mitA↑, ROS↓, P-gp/ABCB1↓, MDR1↓, RadioS↑, Apoptosis↑, GSH↓, lipid-P↑, Iron↑, Iron↓, Fenton↑,
8675- MLT,    Melatonin combined with antineoplastic drugs or natural products for cancer treatment: An update
- Review, Var, NA
ChemoSen↑, TumCP↓, TumCMig↓, CSCs↓, MDR1↓, chemoP?, IL1β↓, IL6↓, IL8↓, TNF-α↓, COX2/PTGS2↓, iNOS↓, Bcl-2↓, Mcl-1↓, IAP1↓, survivin↓, PCNA↓, Ki-67↓, CC(CDKs/cyclins)↓, TumCMig↓, TumCI↓, Fibronectin↓, Vim↓, N-cadherin↓, MMP2↓, MMP9↓, Synergy↑, Synergy↑, OCT4↓, Nanog↓, ERCC1↓, P-gp/ABCB1↓, EMT↓, Synergy↑, ChemoSen↑,
9011- Phyco,    Phycocyanin: A Potential Drug for Cancer Treatment
- Review, Var, NA
*antiOx↑, *Inflam↓, *AntiCan↑, *Imm↑, *RenoP↑, *hepatoP↑, Synergy↑, EMT↓, TumCCA↑, P21↑, cycE/CCNE↓, CDK2↓, Cyt‑c↑, Casp↑, cl‑PARP1↑, Bax:Bcl2↑, MMP↓, ROS↑, CD59↑, Fas?, IL1β↓, IL2↓, IFN-γ↓, TNF-α↓, JAK3↓, STAT3↓, IL4↑, COX2/PTGS2↓, PGE2↓, MMP9↓, MMP2↓, MMP9↓, TIMP2↓, Vim↓, COL1↓, E-cadherin↑, MDR1↓, AP-1↓, ChemoSen↑, chemoP↑, RadioS↑, TumAuto↑,
2946- PL,    Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent
- Review, Var, NA
ROS↑, GSH↓, DNAdam↑, ChemoSen↑, RadioS↑, BioEnh↑, selectivity↑, BioAv↓, eff↑, p‑Akt↓, mTOR↓, GSK‐3β↓, β-catenin/ZEB1↓, HK2↓, Glycolysis↓, Cyt‑c↑, Casp9↑, Casp3↑, Casp7↑, cl‑PARP↑, TrxR↓, ER Stress↑, ATF4↝, CHOP/DDIT3↑, Prx4↑, NF-kB↓, cycD1/CCND1↓, CDK4↓, CDK6↓, p‑RB1↓, RAS↓, cMyc↓, TumCCA↑, selectivity↑, STAT3↓, NRF2↑, HO-1↑, PTEN↑, P-gp/ABCB1↓, MDR1↓, MRP1/ABCC1↓, survivin↓, Twist↓, AP-1↓, Sp1/3/4↓, STAT1↓, STAT6↓, SOX4↑, XBP-1↑, P21↑, eff↑, Inflam↓, COX2/PTGS2↓, IL6↓, MMP9↓, TumMeta↓, TumCI↓, ICAM-1↓, CXCR4↓, VEGF↓, angioG↓, Half-Life↝, BioAv↑,
3347- QC,    Recent Advances in Potential Health Benefits of Quercetin
- Review, Var, NA - Review, AD, NA
*antiOx↑, *ROS↓, *Inflam↓, TumCP↓, Apoptosis↑, *cardioP↑, *BP↓, TumMeta↓, MDR1↓, NADPH↓, ChemoSen↑, MMPs↓, TIMP2↑, *NLRP3↓, *IFN-γ↑, *COX2/PTGS2↓, *NF-kB↓, *MAPK↓, *CRP↓, *IL6↓, *TNF-α↓, *IL1β↓, *TLR4↑, *PKCδ↓, *AP-1↓, *ICAM-1↓, *NRF2↑, *HO-1↑, *lipid-P↓, *neuroP↑, *Synergy↑, *memory↑, *cognitive↑, *AChE↓, *BioAv↑, *BioAv↑, *BioAv↑, *BioAv↑, *BioAv↑,
2687- RES,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, NA, NA - Review, AD, NA
NF-kB↓, P450↓, COX2/PTGS2↓, Hif1a↓, VEGF↓, *SIRT1↑, SIRT1↓, SIRT2↓, ChemoSen⇅, cardioP↑, *memory↑, *angioG↑, *neuroP↑, STAT3↓, CSCs↓, RadioS↑, Nestin↓, Nanog↓, TP53↑, P21↑, CXCR4↓, *BioAv↓, EMT↓, Vim↓, Slug↓, E-cadherin↑, AMPK↑, MDR1↓, DNAdam↑, TOP2↓, PTEN↑, Akt↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MALAT1↓, TCF↓, ALDH↓, CD44↓, Shh↓, IL6↓, VEGF↓, Synergy↑, HK2↓, ROS↑, MMP↓,
1744- RosA,    Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity
- Review, Var, NA
chemoR↓, ChemoSideEff↓, RadioS↑, ROS↓, ChemoSen↑, BioAv↑, Half-Life↝, antiOx↑, ROS↑, Fenton↑, DNAdam↑, Apoptosis↑, CSCs↓, HH↓, Bax:Bcl2↑, MDR1↓, P-gp/ABCB1↓, Synergy↑, eff↑, FOXO4↑, *eff↑, *ROS↓, *JNK↓, *ERK↓, *GSH↑, *H2O2↑, *MDA↓, *SOD↑, *HO-1↑, *CardioT↓, selectivity↑,
4907- Sal,    A comprehensive review of salinomycin derivatives as potent anticancer and anti-CSCs agents
- Review, Var, NA
Apoptosis↑, MDR1↓, CSCs↓,
3327- SIL,    Effects of silymarin on HIF‑1α and MDR1 expression in HepG‑2 cells under hypoxia
- in-vitro, Liver, HepG2
MDR1↓, Hif1a↓, P-gp/ABCB1↓,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2/PTGS2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
2094- TQ,    Cytotoxicity of Nigella sativa Extracts Against Cancer Cells: A Review of In Vitro and In Vivo Studies
- Review, Var, NA
ROS↑, angioG↓, TumMeta↓, VEGF↓, MMPs↓, P53↑, BAX↑, Casp↑, Bcl-2↓, survivin↓, *ROS↓, ChemoSen↑, chemoP↑, MDR1↓, BioAv↓, BioAv↑,

Showing Research Papers: 1 to 35 of 35

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 35

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Fenton↑, 2,   GPx4↓, 1,   GSH↓, 3,   HO-1↓, 1,   HO-1↑, 1,   Iron↓, 1,   Iron↑, 1,   c-Iron↑, 1,   lipid-P↑, 2,   NRF2↓, 2,   NRF2↑, 2,   Prx4↑, 1,   ROS↓, 2,   ROS↑, 16,   mt-SOD↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

Bfl-1↓, 1,   CDC2↓, 1,   compI↓, 1,   mitResp↓, 1,   mtDam↑, 3,   OCR↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↑, 1,   AMPK↑, 3,   ATP↓, 2,   GlucoseCon↓, 1,   Glycolysis↓, 2,   GSK‐3β↓, 2,   p‑GSK‐3β↓, 1,   HK2↓, 2,   lactateProd↓, 1,   LAR↓, 1,   LDHA↓, 1,   NADPH↓, 1,   PKM2↓, 1,   PKM2↑, 1,   SIRT1↓, 1,   SIRT2↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 12,   BAX↑, 5,   Bax:Bcl2↑, 5,   Bcl-2↓, 7,   Bcl-xL↓, 2,   Casp↑, 4,   Casp3↑, 4,   cl‑Casp3↑, 2,   Casp7↑, 2,   cl‑Casp8↑, 2,   Casp9↑, 2,   cl‑Casp9↑, 2,   cFLIP↓, 1,   Cyt‑c↑, 5,   DR5↑, 2,   Fas?, 1,   Fas↑, 1,   Ferroptosis↑, 2,   IAP1↓, 3,   IAP2/BIRC3↓, 1,   ICD↑, 1,   iNOS↓, 2,   Mcl-1↓, 1,   MDM2↓, 1,   Pyro↑, 1,   RIP3↑, 1,   survivin↓, 5,   TRAIL↑, 1,   XIAP↓, 2,   YAP/TEAD↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 10,   Akt↑, 1,   p‑Akt↓, 3,   BRAF↓, 1,   CaMKII ↓, 1,   DYRK1B↓, 1,   ERK↓, 1,   ERK↑, 1,   JAK3↓, 1,   JNK↑, 2,   MAPK↓, 2,   MEK↓, 2,   mTOR↓, 10,   p‑mTOR↓, 1,   PI3K↓, 6,   PTEN↑, 3,   RAS↓, 2,   RIP1↑, 1,   Sp1/3/4↓, 1,   Src↓, 1,   STAT3↓, 5,   STAT3↝, 1,   STAT6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↝, 1,   cMyc↓, 4,   cMyc↑, 1,   p‑cMyc↑, 1,   DNMT1↓, 1,   DNMT3B↓, 1,   FOXO4↑, 1,   HIST1H3B?, 1,   Myc↓, 1,   OCT4↓, 2,   other↑, 1,   other↝, 1,   SOX2↓, 2,   SOX4↓, 1,   SOX4↑, 1,   TFE3↑, 1,   tumCV↓, 3,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 2,   ER Stress↑, 4,   HSP27↓, 1,   UPR↑, 1,   XBP-1↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG5↑, 1,   Beclin-1/ATG6↑, 2,   LC3B-II↑, 1,   LC3II↑, 1,   p62↓, 1,   TumAuto↑, 7,  

DNA Damage & Repair(tgid=10) ⓘ

DFF45↓, 1,   DNAdam↑, 8,   ERCC1↓, 1,   hTERT/TERT↓, 2,   P53↑, 5,   cl‑PARP↑, 4,   cl‑PARP1↑, 1,   PCNA↓, 1,   Telomerase↓, 2,   TOP2↓, 2,   TP53↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CC(CDKs/cyclins)↓, 1,   CDK1↓, 2,   CDK2↓, 2,   CDK4↓, 1,   CDK6↓, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↓, 5,   cycE/CCNE↓, 1,   Ki-67↓, 1,   mitA↑, 2,   P21↓, 1,   P21↑, 6,   p‑RB1↓, 1,   TubPol↓, 1,   TumCCA↑, 15,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   CD133↓, 1,   CD24↓, 1,   CSCs↓, 7,   Gli1↓, 2,   HH↓, 4,   Ki-67↓, 1,   Nanog↓, 5,   Nestin↓, 1,   NICD↓, 1,   NOTCH1↓, 2,   PTCH2↓, 1,   Shh↓, 2,   Smo↓, 1,   STAT1↓, 1,   TAZ↓, 1,   TumCG↓, 6,   TumCP↓, 12,   Wnt↓, 6,  

Migration(tgid=13) ⓘ

AEG1↓, 1,   AP-1↓, 2,   Ca+2↑, 4,   Chl↑, 1,   COL1↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 4,   EMT↓, 9,   FAK↓, 1,   Fibronectin↓, 1,   MALAT1↓, 1,   MMP13↓, 1,   MMP2↓, 5,   MMP7↓, 2,   MMP9↓, 9,   MMPs↓, 4,   N-cadherin↓, 3,   PAK1↓, 2,   Slug↓, 1,   SMAD3↑, 1,   TIMP1↑, 2,   TIMP2↓, 2,   TIMP2↑, 2,   TumCI↓, 2,   TumCMig↓, 2,   TumMeta?, 1,   TumMeta↓, 5,   Twist↓, 1,   uPA↓, 2,   Vim↓, 4,   β-catenin/ZEB1↓, 5,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 10,   angioG↑, 1,   Hif1a↓, 4,   NO↑, 1,   VCAM-1↓, 1,   VEGF↓, 13,   VEGFR2/KDR/Flk1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 3,   CellMemb↑, 1,   EPR↑, 1,   MMP↓, 7,   MPT↑, 1,   TRPV1↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD44↓, 5,   CD59↑, 1,   COX2/PTGS2↓, 8,   CXCR4↓, 4,   DR4↑, 1,   Eos↑, 1,   HCAR1↓, 1,   ICAM-1↓, 2,   IFN-γ↓, 2,   IL12↑, 1,   IL1β↓, 2,   IL2↓, 1,   IL2↑, 1,   IL4↑, 1,   IL6↓, 4,   IL8↓, 1,   Imm↑, 2,   Imm↝, 1,   Inflam↓, 1,   M2 MC↓, 1,   MCP1/CCL2↓, 1,   MCT1↓, 1,   MyD88↑, 1,   Neut↑, 1,   NF-kB↓, 9,   p‑NF-kB↑, 1,   PD-L1↓, 1,   PGE2↓, 1,   PSA↓, 1,   TCF↓, 2,   TLR4↑, 1,   TNF-α↓, 3,   TNF-α↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH↓, 1,   pH↑, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

SYN1↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 2,   PPARγ↑, 1,   PXR, NR1I2↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↓, 5,   BioAv↑, 7,   BioEnh↑, 2,   chemoR↓, 1,   ChemoSen?, 1,   ChemoSen↓, 1,   ChemoSen↑, 23,   ChemoSen⇅, 1,   CYP3A4↓, 1,   Dose↝, 4,   eff↓, 2,   eff↑, 7,   GSTA1↓, 1,   Half-Life↝, 4,   MDR1↓, 34,   MDR1↑, 1,   MRP1/ABCC1↓, 3,   P-gp/ABCB1↓, 13,   P450↓, 1,   RadioS?, 1,   RadioS↑, 7,   selectivity↑, 3,   Synergy↑, 10,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 2,   BRAF↓, 1,   hTERT/TERT↓, 2,   IL6↓, 4,   Myc↓, 1,   PD-L1↓, 1,   PSA↓, 1,   TP53↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   antiNeop↑, 1,   AntiTum↑, 1,   cardioP↑, 1,   chemoP?, 1,   chemoP↑, 4,   ChemoSideEff↓, 1,   OS↑, 2,   QoL↑, 2,   radioP↑, 1,   toxicity↓, 1,   toxicity↝, 1,   TumVol↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 294

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 5,   GPx4↑, 1,   GSH↑, 2,   H2O2↑, 1,   HO-1↑, 3,   i-Iron↓, 1,   lipid-P↓, 2,   MDA↓, 2,   NRF2↑, 3,   ROS↓, 5,   SOD↑, 1,   xCT/SLC7A11↑, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Ferroptosis↓, 2,  

Kinase & Signal Transduction(tgid=6) ⓘ

ERK↓, 1,   JNK↓, 1,   MAPK↓, 1,   PKCδ↓, 1,  

Migration(tgid=13) ⓘ

AP-1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   ICAM-1↓, 1,   IFN-γ↑, 1,   IL1β↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 4,   NF-kB↓, 1,   NK cell↑, 1,   NLRP3↓, 1,   TLR4↑, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

AChE↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 2,   BioAv↑, 6,   Dose↝, 1,   eff↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

BP↓, 1,   CRP↓, 1,   IL6↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   AntiDiabetic↑, 1,   cardioP↑, 1,   CardioT↓, 1,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 2,   neuroP↑, 2,   RenoP↑, 1,   toxicity↓, 2,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1,   Bacteria↓, 1,   GutMicro↑, 1,  
Total Targets: 57

Scientific Paper Hit Count for: MDR1, Multidrug Resistance 1
2 Berberine
2 Cisplatin
2 borneol
2 itraconazole
2 Ivermectin
2 Luteolin
1 Astragalus
1 Berbamine
1 Chemotherapy
1 Caffeic Acid Phenethyl Ester (CAPE)
1 Celecoxib
1 Chrysin
1 5-fluorouracil
1 Curcumin
1 Evodiamine
1 Gambogic Acid
1 Genistein (soy isoflavone)
1 iodine
1 Isorhamnetin
1 Kaempferol
1 Lemongrass Extract/Citral
1 doxorubicin
1 mebendazole
1 Magnetic Fields
1 Melatonin
1 Phycocyanin
1 Piperlongumine
1 Quercetin
1 Resveratrol
1 Rosmarinic acid
1 salinomycin
1 Silymarin (Milk Thistle) silibinin
1 Shikonin
1 Thymoquinone
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:741  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page